イチキ　ヨシノブ   ICHIKI Yoshinobu   市来　嘉伸    所属   埼玉医科大学  医学部 国際医療センター　呼吸器外科    職種   専任講師
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung.
掲載誌名	正式名：Surgical case reports
巻・号・頁	4(1),19-19頁
著者・共著者	Naoko Imanishi,Kazue Yoneda,Akihiro Taira,Yoshinobu Ichiki,Naoko Sato,Masanori Hisaoka,Fumihiro Tanaka
発行年月	2018/03
概要	BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene. Here, we present the first surgical case of ALK-rearranged lung adenocarcinoma with major pathological response in resected specimens after treatment with alectinib. CASE PRESENTATION: A 65-year-old female with clinical stage IIIA-N2 ALK-rearranged adenocarcinoma originating from the left lower lobe presented. Involvement of lower para-tracheal node was pathologically confirmed by endobronchial ultrasound-guided biopsy. Alectinib was prescribed, as the patient may not tolerate radiotherapy due to a mental illness. After 3 months' treatment with alectinib, a remarkable radiological and metabolic response was achieved. The patient did not tolerate further continuation of alectinib treatment, and surgery was performed without any morbidity. Only< 10% tumor cells were viable in all resected specimens, indicating major pathological response to alectinib. CONCLUSIONS: Salvage surgery afte
DOI	10.1186/s40792-018-0430-7
PMID	29524063